| PRECLINICAL | evidence | Is There a Causal Link Between GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischaemic Optic Neuropathy? A Critique of the Clinical Evidence. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Acute Systemic Complications Following High-Dose Semaglutide Reinitiation in an Elderly Patient. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide and tirzepatide for obesity: A summary from the Institute for Clinical and Economic Review's New England Comparative Effectiveness Public Advisory Council. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | GLP-1R-GIPR-PPARalpha/gamma/delta quintuple agonism corrects obesity and diabetes in mice. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Emerging risk of non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide: a safety alert for clinicians. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Thermally Stressed Solid-State Stability of Semaglutide: Understanding the Influence of Temperature on Protein Content, Secondary Structure, Phase Transition, and Chemical Degradation. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Pharmacological therapy in the obese patient: is it only a matter of fat loss? | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction-associated steatotic liver disease treated with semaglutide: A case series. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | A retrospective audit of weight loss and health outcomes following bariatric surgery at a tertiary public hospital. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Advances in GLP-1 receptor agonists delivery systems for obesity and diabetes. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Quadruple Non-Insulin Therapy for Advanced Type 2 Diabetes Mellitus With Cognitive Impairment: A Case Report. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Peri-Procedural Fasting and Gastric Ultrasound Strategies in Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Users: A Systematic Review With Qualitative Synthesis. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. | Wegovy | Liver health | 2026-05-01 |
| PRECLINICAL | evidence | Sex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States. | Ozempic | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide: Real World Results, Realistic Recommendations. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Exploring the surge of Ozempic in Pakistan:Are we overlooking its oral health impact? | Ozempic | — | 2026-05-01 |
| PRECLINICAL | evidence | The efficacyand safety of once weekly injectable semaglutide (Ozempic) among patients with Type 2 diabete sintertiary care hospital: A Retrospective Study. | Ozempic | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Efficacy and Safety of Oral Semaglutide in the Management of Diabetes and Obesity: A Comprehensive Meta-analysis of Real-world Evidence. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Comment on 'Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World (STEER)'. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Heterogeneity of Treatment Effects of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss in Adults: A Systematic Review and Meta-Analysis. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Weight loss as the optimal cardiometabolic management strategy for preventing and treating heart failure. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. | Semaglutide | Mood & anxiety | 2026-05-01 |
| PRECLINICAL | evidence | Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials. | Semaglutide | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide in patients with hidradenitis suppurativa and obesity. | semaglutida | Weight & fat loss | 2026-05-01 |
| PRECLINICAL | evidence | Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | The Role of Glucagon-like Peptide 1 Receptor Modulators for the Management of Dumping Syndrome in Patients Who have Undergone Metabolic and Bariatric Surgery: a Scoping Review. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Semaglutide and Follow-On Peptide Therapeutics: Balancing Innovation, Regulation, and Clinical Outcomes. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | AISF practice guidance on pharmacological treatment of metabolic-dysfunction associated steatotic liver disease and steatohepatitis (MASLD/MASH): A 2026 Update. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | TikTokfluence: The rise of GLP-1 receptor agonists in the age of social media health trends. | Ozempic | — | 2026-05-01 |
| PRECLINICAL | evidence | Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. | Semaglutide | Glycemic control | 2026-05-01 |
| PRECLINICAL | evidence | Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report. | Semaglutide | — | 2026-05-01 |
| PRECLINICAL | evidence | Advancing precision health discovery in a genetically diverse health system. | Semaglutide | Glycemic control | 2026-04-30 |
| PRECLINICAL | evidence | Semaglutide Induces Changes in Gastric Electrical Activity in Patients With Overweight and Obesity: A Pilot Study. | Semaglutide | — | 2026-04-30 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists and Ocular Outcomes: Metabolic Transition, Retinal Vulnerability, and Risk-Stratified Monitoring. | Semaglutide | — | 2026-04-30 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 Receptor Agonists for Mood Disorders and Suicide Risk. | Semaglutide | — | 2026-04-30 |
| PRECLINICAL | evidence | Use of semaglutide and tirzepatide among people with multiple sclerosis. | Semaglutide | — | 2026-04-29 |